Cannabidiol for seizures

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 7 registered trials.

Why this status

  1. 17 Dec 2014: Trial registered, NCT02318602
  2. 8 Jan 2016: Trial started, NCT02318602

The trials

NCT02318602: Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

State
Completed
Phase
Phase 3
People
52 taking part
Started
8 Jan 2016
Primary completion
22 Jun 2017
Arms
Infants, Children, Adolescents
Results
Posted on the registry
  1. 17 Dec 2014: Trial registered
  2. 8 Jan 2016: Trial started
  3. 22 Jun 2017: Trial completed
  4. 26 Jul 2018: Trial results posted

NCT02324673: Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

State
Completed
Phase
Phase 1 and Phase 2
People
61 taking part
Started
13 Apr 2015
Primary completion
9 May 2016
Arms
Low Dose Cannabidiol Oral Solution [10 mg/kg/day], Mid Dose Cannabidiol Oral Solution [20 mg/kg/day], High Dose Cannabidiol Oral Solution [40 mg/kg/day]
Results
Posted on the registry
  1. 24 Dec 2014: Trial registered
  2. 13 Apr 2015: Trial started
  3. 9 May 2016: Trial completed
  4. 23 Jun 2017: Trial results posted

NCT02695537: University of Alabama at Birmingham (UAB) Pediatric CBD Program

State
Completed
Phase
Phase 1
People
89 taking part
Started
Apr 2015
Primary completion
27 Feb 2019
Arms
Epidiolex 100 milligram/milliliter (mg/mL) oral solution
Results
Posted on the registry
Papers
doi:10.1016/j.yebeh.2019.03.042, doi:10.1080/13554794.2017.1391294
  1. 1 Mar 2016: Trial registered
  2. 27 Feb 2019: Trial completed
  3. 10 Apr 2020: Trial results posted

NCT02700412: University of Alabama at Birmingham (UAB) Adult CBD Program

State
Completed
Phase
Phase 1
People
80 taking part
Started
Apr 2015
Primary completion
8 Aug 2019
Arms
Epidiolex 100 milligram/milliliter (mg/mL) oral solution
Results
Posted on the registry
Papers
doi:10.1016/j.yebeh.2019.03.042, doi:10.1080/13554794.2017.1391294
  1. 7 Mar 2016: Trial registered
  2. 8 Aug 2019: Trial completed
  3. 8 May 2020: Trial results posted

NCT04485104: Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

State
Stopped early
Phase
Phase 3
People
3 taking part
Started
19 May 2021
Primary completion
28 Jan 2025
Arms
GWP42003-P
Results
Posted on the registry
  1. 24 Jul 2020: Trial registered
  2. 19 May 2021: Trial started
  3. 28 Jan 2025: Trial terminated
  4. 31 Oct 2025: Trial results posted

NCT05288283: Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

State
Stopped early
Phase
Phase 3
People
3 taking part
Started
31 Oct 2022
Primary completion
28 Sep 2023
Arms
GWP42003-P
Results
Posted on the registry
  1. 21 Mar 2022: Trial registered
  2. 31 Oct 2022: Trial started
  3. 28 Sep 2023: Trial terminated
  4. 3 Feb 2025: Trial results posted

NCT06924827: A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex

State
Not started
Phase
Phase 4
People
25 planned
Started
1 Jan 2027
Primary completion
1 Jan 2028
Arms
Epidiolex Treatment
Results
None posted
  1. 11 Apr 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Cardiolrx, Canapure PH, Cannabidiol (Epidiolex), Cannabidiol Oral Solution, Epidiolex, Epidiolex 100 mg/mL Oral Solution, Epidyolex, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose, GWP42003-P 5 mg/kg/day Dose, MediCabilis.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.